Beijing Tiantan Biological Products Co., Ltd.
600161
Rangering i aksjer
#4320
Beijing Tiantan Biological Products Co., Ltd., established in 1998 and... Beijing Tiantan Biological Products Co., Ltd., established in 1998 and headquartered in Beijing, China, is actively involved in the full spectrum of blood product operations within China. This includes pioneering research and development, manufacturing, sales, and providing consultancy services. Its comprehensive product line features critical blood-derived medicines such as intravenous immunoglobulin, human albumin, and various specialized human immunoglobulins for conditions like hepatitis B (both standard and freeze-dried formulations) and tetanus, alongside other general human immunoglobulin preparations and intravenous blood system solutions. The company operates as a subsidiary of China National Biotec Group Company Limited.
Aksjekurs
$1.81
Markedsverdi
$3.59B
Endring (1 dag)
-0.90%
Endring (1 år)
-32.39%
Land
CN
Handel Beijing Tiantan Biological Products Co., Ltd. (600161)
Kategori
Healthcare
Inntekter for Beijing Tiantan Biological Products Co., Ltd. (600161)
Inntekter i Oct 2026 TTM: 0
Ifølge de nyeste økonomiske rapportene til Beijing Tiantan Biological Products Co., Ltd. er selskapets nåværende inntekter (TTM) 0. I 2026 hadde selskapet inntekter på 0 lik inntektene i 2026, som var 0. Inntektene er det totale beløpet et selskap genererer fra salg av varer eller tjenester. I motsetning til fortjeneste trekkes ingen kostnader fra.
Inntektshistorikk for Beijing Tiantan Biological Products Co., Ltd. fra 2001 til 2026
Inntekter ved slutten av hvert år
| År | Inntekter | Endre |
|---|---|---|
| 2025 | $877.40M | 6.17% |
| 2024 | $826.38M | 12.92% |
| 2023 | $731.85M | 18.47% |
| 2022 | $617.77M | -4.52% |
| 2021 | $646.98M | 22.66% |
| 2020 | $527.44M | 11.91% |
| 2019 | $471.31M | 10.61% |
| 2018 | $426.11M | 11.64% |
| 2017 | $381.67M | 23.92% |
| 2016 | $308.00M | 23.62% |
| 2015 | $249.16M | -15.51% |
| 2014 | $294.89M | -2.60% |
| 2013 | $302.76M | 25.67% |
| 2012 | $240.92M | 8.92% |
| 2011 | $221.19M | 21.43% |
| 2010 | $182.15M | 13.03% |
| 2009 | $161.16M | 61.08% |
| 2008 | $100.05M | 37.71% |
| 2007 | $72.66M | 37.07% |
| 2006 | $53.01M | 24.61% |
| 2005 | $42.54M | 21.37% |
| 2004 | $35.05M | 18.43% |
| 2003 | $29.59M | 22.68% |
| 2002 | $24.12M | 28.78% |
| 2001 | $18.73M | 0.00% |
Inntekter for lignende selskaper eller konkurrenter
| Selskap | Inntekter | Forskjell i inntekter | Land |
|---|---|---|---|
| $12.62B | - |
US
|
|
| $2.23B | - |
US
|
|
| $15.74B | - |
AU
|
|
| $6.02B | - |
NL
|
|
| - | - |
CH
|
